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Chiral Nb-Fmoc amino alkyl isonitriles were employed in Ugi multi component reactions (Ugi 4C-3CR) to
obtain functionalized b-lactam peptidomimetics with L-aspartic acid a-methyl ester/peptide ester and
organic aldehydes. The reactions were carried out in MeOH. Thirteen Ugi products have been prepared
in good to moderate yields with good diastereoselectivities.
 2011 Elsevier Ltd. All rights reserved.N
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Figure 1. Representative examples of reported b-lactam peptidomimetics.Multi-component reactions (MCRs)1 have become vital tools for
assembling complex molecules and hence new MCRs are being de-
signed for the construction of novel molecules.2 Isonitrile based
MCRs have gained renewed attention due to their unique reactivity
to function as electrophile as well as nucleophile.3 They have been
the key components in Pessirini 3CRs and Ugi-4CRs employed
widely for generating molecular libraries.4 Ugi-MCRs, over the
years, have undergone improvements with respect to improvingll rights reserved.
obile: +91 9986312937.
ail.com, hariccb@gmail.com,
O
R1 NH
R2
COO
R3-NC
R1 N
H
O
R2
N
O
R3 R
3
H
N
O
N
R2
O R1
β -lactam derivativeSchiff's base oxazepinone
..
General mechanism for the formation of b-lactam ring through Ugi 4C-3CR.
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Scheme 2. Synthesis of Nb-Fmoc amino alkyl isonitriles.
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Scheme 3. Synthesis of b-lactam peptidomimetics.
Table 1
List of b-lactam peptidomimetics synthesized
Entry Isonitriles 2 Ugi producta 3 Yieldb (%) d.r.c HRMS [M+H]+ (obsd/calcd)
a
FmocHN
NC
FmocHN
H
N
O
N
O
COOMe
Ph
65 99:1 528.2108/528.2135
b
FmocHN
NC
FmocHN
H
N
O
N
O
COOMe
Ph
78 96:4 542.2280/542.2286
c FmocHN
NC
Ph
FmocHN
H
N
O
N
O
COOMe
Ph
69 85:15 598.2903/598.2912
d FmocHN
NC
FmocHN
H
N
O
N
O
COOMe
72 90:10 494.2276/494.2286
e FmocHN
NC
OBn
FmocHN
H
N
O
N
O
COOMe
BnO
Ph
76 89:11 648.2697/648.2704
f
FmocHN
NC
COOBzl
FmocHN
H
N
O
N
O
COOMe
BnOOC
63 100:0 656.2952/656.2966
g FmocHN
NC
NHZ
4
FmocHN
H
N
O
N
O
COOMe
ZHN
4
59 98:2 657.2902/657.2919
h
N
Fmoc
NC
N
Fmoc
H
N
N
O
Ph
O
COOMe
53 95:5 568.2429/568.2442
a b-Amino acid component employed was H-Asp(b-OH)-OMe.
b Isolated yields after column chromatography.
c Diastereomeric ratios of the products were measured by 1H NMR of the puriﬁed products.
T. M. Vishwanatha et al. / Tetrahedron Letters 52 (2011) 5620–5624 5621the yield and diastereoselectivity.5 They have been largely em-
ployed in one-pot synthesis of peptides and peptidomimetics.6,7A promising application of Ugi MCR focuses on the synthesis of
b-lactam derivatives.8 b-Lactams are powerful antibacterials9 and
5622 T. M. Vishwanatha et al. / Tetrahedron Letters 52 (2011) 5620–5624show an array of bioactivities, such as inhibition of ser, cys, and
HIV-I proteases.10 They also ﬁnd synthetic applications as b-amino
acid precursors and in the synthesis of short peptide segments.11
Despite the wide spread utility of b-lactam units,12 there is still
requirement for highly functionalized b-lactam units (Fig. 1).
For the synthesis of b-lactam derivatives, Staudinger reaction
involving [2+2] cycloaddition of ketenes and imines has been the
widely used protocol.13 Solid phase synthetic protocols are also de-
scribed mainly based on [2+2] cycloaddition of ketene with resin
bound imine.14 Podlech’s group has synthesized b-lactam pepti-
domimetics in solution through photochemical decomposition of
amino acid derived diazoketones in the presence of amino acid
or peptide derived imines.15 Palomo et al. synthesized a,a0-disub-
stituted b-lactam scaffolds through ring opening of a-substituted-
a-methoxycarbonyl-N-nosyl aziridines with amino acid esters.16 A
single step approach for the construction of oligopeptide-like back
bone containing b-lactam ring was reported on a steroid molecule
by Ugi et al.17 Thereafter, Ugi MCRs have been used to construct a
variety of b-lactam compounds starting from b-amino acids, alde-
hydes, and isonitriles. Among them L-aspartic acid a-benzyl ester,
enantiopure cyclic b-amino acids, and simple b-amino acids have
been widely employed as b-amino acid components.18
Chiral a-isocyanato esters have been most commonly employed
as components inmajority ofMCRs for the synthesis of peptides and
backbone modiﬁed peptides.19 Despite signiﬁcant contributions by
optically pure isocyanato esters to MCRs, ideally, the N-protected
amino alkyl isonitriles as C-terminally modiﬁed amino acid deriva-
tives might even act as useful function for further modiﬁcation of
peptides inMCRs.We have reported the synthesis of amino acid de-
rived isonitriles of the type Nb-Fmoc-CHR-w[CH2NC] via the –COOH
end modiﬁcation.20 The Nb-Fmoc amino alkyl isonitriles when used
in MCRs would increase the diversity of products than what can be
obtained through classical isonitriles of the type CN–CHR–COOY de-
scribedbyUgi et al.4a In this regard,wehave initiated synthetic stud-
ies on the application of these isonitriles in MCRs to generate a new
class of peptidomimetics. The work described herein illustrates the
preparation of b-lactam-linked peptidomimetics through Ugi four-
center three-component reaction (Ugi 4C-3CR) of Nb-Fmoc-aminoFmocHN
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Figure 2. List of b-lactam bearing peptidomimetics. b-Amino acid components employealkyl isonitriles, L-aspartic acid a-methyl ester/peptide esters, and
aldehydes. The reaction also represents a simple method to insert
b-lactam units into the peptide backbone.
A probable accepted mechanism for the formation of b-lactam
derivatives is represented in Scheme 1. Condensation of b-amino
acid with appropriate aldehyde affords protonated Schiff’s base,
which reacts with an isonitrile to generate an oxazepinone inter-
mediate. The latter would be transferred to b-lactam derivative
through intramolecular N,O-acyl migration (Scheme 1).
In the ﬁrst part of our work, Nb-Fmoc-amino alkyl isonitriles 2,
the key intermediates for the proposed reaction were prepared fol-
lowing the reported procedure. In brief, Nb-Fmoc-amino alkyl iso-
cyanates (obtained from Nb-Fmoc-amino acids) were directly
formulated by treating with formic acid under DMAP catalyzed
Goldsmith–Wick condition with 98% formic acid and the resulting
formamides were reacted with Burgess reagent under neutral con-
dition. All the isonitriles were obtained in good yield with the
retention of chiral integrity (Scheme 2).
In the next part, syntheses of different b-amino acid compo-
nents 1 required for Ugi multi component condensation were
undertaken. Starting with Z-Asp(b-OBn)-OH, employing standard
peptide coupling protocols, several di and tripeptide methyl esters
were prepared. After removal of Z and benzyl esters of Asp residue
under catalytic hydrogenolysis (Pd/C, H2), the required H-Asp-Xaa-
OMe derivatives were obtained in good yield.21,22
Having the key reactants in hand, we focused on the assembly of
b-lactamderivedpeptidomimetics. In a typical reaction a solution of
Nb-Fmoc-Ala-w[CH2NC] 2b in methanol was stirred with equimolar
quantity of benzaldehyde and H-Asp-OMe 1a at rt.23 After 24 h, al-
most complete consumption of the isonitrile was observed as ana-
lyzed by TLC (Scheme 3). Removal of the solvent followed by a
simple work-up afforded the desired product in satisfactory yield.
Column chromatographic separation (silica gel 100–200 mesh;
EtOAc: n-hexane-8:2) afforded the pure compound 3b as solid in
78%yield. As expected, the chiral HPLC analysis of the crude reaction
mixture had two peaks corresponding to the two diastereomeric
products in the ratio 96:4,24 however, no attempts were made to
separate the isomers.25 Further, to explore the efﬁciency and scopeFmocHN
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T. M. Vishwanatha et al. / Tetrahedron Letters 52 (2011) 5620–5624 5623of the present protocol, a series of b-lactam derivatives were pre-
pared by varying the isonitriles derived from Nb-Fmoc-amino acids
and aldehyde components (3a–j) keeping H-Asp-OMe as a common
reactant.26 All the reactionswere completewith in 24–28 hunder rt,
resulting in the b-lactam derivatives inmoderate to good yield with
diastereomeric ratio varying from 100:0 to 85:15 (Table 1). It is
known from the literature, a good diastereoselectivity is achieved
during b-lactam synthesis through Ugi 4C-3CR due to the formation
of sevenmembered oxapinone intermediate. Further, an attempt to
decrease the reaction time and to improve the yields of the Ugi ad-
ducts was undertaken with compound Nb-Fmoc-Phe-w[CH2NC] 2c
as the model reactant. The reaction was also carried out at reﬂux
for 8–10 h or ultrasonication at 80 C for 7–9 h during which com-
plete disappearance of the isonitrile was observed, but these condi-
tions did not improve the yield signiﬁcantly or the
diastereoselectivity. Hence,mild conditionswere eventually chosen
to synthesize title molecules (Scheme 3). Isonitriles derived from
several side chain functionalized amino acids viz Fmoc-Ser(OBn)-
OH, Fmoc-Asp(b-OBn)-OH, Fmoc-Lys(Z)-OH were also used in the
reaction and the products were obtained in good yield without the
formation of byproducts.
Encouraged by these results, additional set of peptidomimetics
3i–m, bearing endo-b-lactam units were prepared by utilizing pep-
tide esters with N-terminal Asp residue 1b–e. Ugi reaction was car-
ried out by varying all the three components. Compared to the
reactions involving 1a as b-amino acid component, those involving
1b–e were sluggish and even after running the reaction to 48 h,
only moderate yields were obtained (Fig. 2).27 All the compounds
were isolated as stable ones and characterized through IR, mass,
1H NMR and 13C NMR analyses.
In conclusion, we have accomplished the ﬁrst application of
chiral Nb-Fmoc-amino alkyl isonitriles in Ugi multi component
reactions through the synthesis of peptide mimics with b-lactam
units. b-Lactams have been synthesized in solution through Ugi
4C-3CR through one-pot condensation of Nb-Fmoc-amino alkyl
isonitriles, L-aspartic acid a-methyl ester/ peptide ester, and com-
mercially available aldehydes.
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155.2, 143.0, 140.8, 136.2, 129.1, 128.8, 128.7, 128.5, 128.2, 127.8, 127.5, 127.3,
127.0, 126.8, 66.5, 59.9, 51.0, 50.5, 47.8, 46.8, 41.2, 16.8.
27. Spectral data for 3l: IR (KBr): m 1752, 1748, 1671, 1550 cm1; 1H NMR (CDCl3,
300 MHz) d 7.78 (d, 2H, J = 6.5 Hz), 7.48 (d, 2H, J = 3.1 Hz), 7.22–7.28 (m, 4H),
7.05–7.19 (m, 5H), 6.36–6.89 (br, 4H), 5.36 and 5.31 (two s, 1H), 4.69 (d, 2H,
J = 2.9 Hz), 4.59–4.61 (m, 1H), 4.44 (t, 1H, J = 6.8 Hz), 4.38 (d, 1H, J = 5.8 Hz),
4.31–4.36 (m, 1H), 3.85 (dd, 1H, J = 2.6, 5.9 Hz), 3.58 (s, 3H), 3.13–3.41 (m, 4H),
1.76–1.81 (m, 1H), 2.11–2.20 (m, 2H), 1.38 (d, 3H, J = 1.8 Hz), 1.08 (d, 6H,
J = 8.1 Hz), 0.96 (d, 6H, J = 5.0 Hz); 13C NMR (CDCl3, 100 MHz) d 170.1, 170.9,
171.0, 167.9, 168.8, 155.0, 142.5, 140.2, 135.8, 129.8, 128.9, 128.5, 128.2, 127.8,
127.6, 127.4, 127.3, 126.7, 126.1, 125.5, 124.5, 119.4, 66.5, 59.9, 55.9, 51.4,
51.0, 49.2, 48.0, 47.1, 44.6, 40.8, 30.0, 23.1, 22.8, 17.1, 17.2, 16.8, 16.7.
